• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Moves Lower; Acuity Brands Earnings Top Estimates

    6/29/23 2:32:01 PM ET
    $AYI
    $BTAI
    $GNLN
    $IMNM
    Building Products
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AYI alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday.

    The Dow traded up 0.68% to 34,081.83 while the NASDAQ fell 0.23% to 13,560.57. The S&P 500, also rose, gaining, 0.28% to 4,389.22.

    Check This Out: Check Out 3 High-Yielding Dividend Stocks In Materials Sector From Wall Street's Most Accurate Analysts

     

    Leading and Lagging Sectors

    • Financials shares jumped by 1.5% on Thursday.

    In trading on Thursday, communication services shares fell by 0.6%.

     

    Top Headline

    Acuity Brands, Inc (NYSE:AYI) reported better-than-expected earnings for its third quarter on Thursday.

    Acuity Brands reported a third-quarter FY23 net sales decline of 5.7% year-over-year to $1.0 billion, missing the consensus of $1.05 billion. Adjusted EPS of $3.75 beat the consensus of $3.71.

     

    Equities Trading UP

    • Sigilon Therapeutics, Inc. (NASDAQ:SGTX) shares shot up 505% to $23.67 after Eli Lilly agreed to acquire the company for $14.92/share in cash.
    • Shares of Eco Wave Power Global AB (NASDAQ:WAVE) got a boost, shooting 23% to $1.9206 after the company announced plans for a share repurchase program of up to 10% of the total number of shares in the company.
    • Immunome, Inc. (NASDAQ:IMNM) shares were also up, gaining 34% to $7.90 after the company and Morphimmune announced a definitive merger agreement and simultaneous private placement investment of $125 million to develop targeted cancer therapies.

     

    Equities Trading DOWN

    • BioXcel Therapeutics, Inc. (NASDAQ:BTAI) shares dropped 66% to $6.08 after the company released topline results from TRANQUILITY II Phase 3 trial of BXCL501 for acute treatment of Alzheimer's Disease-related agitation.
    • Shares of Greenlane Holdings, Inc. (NASDAQ:GNLN) were down 25% to $1.00 after announcing a $4 million public offering.
    • Mobiquity Technologies, Inc. (NASDAQ:MOBQ) was down, falling 27% to $0.1099 after the company reported pricing of $3 million public offering of 30 million shares of common stock at a price of $0.10/share.

    Also Check This Out: Uber, ON Semiconductor And 2 Other Stocks Insiders Are Selling

     

    Commodities

    In commodity news, oil traded up 0.2% to $69.73 while gold traded down 0.3% at $1,917.00.

    Silver traded down 1.2% to $22.81 on Wednesday while copper fell 1.1% to $3.70.

     

    Euro zone

    European shares closed mixed today. The eurozone’s STOXX 600 rose 0.13%, London’s FTSE 100 fell 0.38% while Spain’s IBEX 35 Index rose 0.31% The German DAX fell 0.01% French CAC 40 rose 0.36% and Italy’s FTSE MIB Index rose 1.05%.

    The services confidence indicator in the Eurozone fell for a second straight month to 5.7 in June, while industry confidence indicator dropped for a fifth consecutive month to -7.2 in June. The consumer confidence indicator in was confirmed at -16.1 for the month, while economic sentiment indicator fell for a second month in a row to 95.3 in June.

    Consumer credit in the UK rose by £1.144 billion in May versus a revised £1.513 billion growth in April. Spain's consumer price inflation fell to 1.9% year-over-year in June.

     

    Asia Pacific Markets

    Asian markets closed mixed on Thursday, with Japan’s Nikkei 225 gaining 0.12%, Hong Kong’s Hang Seng Index falling 1.24%, China’s Shanghai Composite Index slipping 0.22%. India’s S&P BSE Sensex gained 0.8%.

    The consumer confidence index in Japan rose to 36.2 in June versus 36 in the prior month, while retail sales rose by 5.7% year-over-year in May. Retail sales in Australia climbed by 0.7% month-over-month to AUD 35.52 billion in May.

     

    Economics

    • Corporate profits in the U.S. dropped by 5.9% to $2.329 trillion in the first quarter.
    • U.S. initial jobless claims declined by 26,000 from the previous week's 20-month high level to 239,000 during the week ending June 24, recording the sharpest drop since October 2021. However, markets were expecting a reading of 265,000.
    • The U.S. economy expanded by an annualized rate of 2% on quarter in the first quarter, higher than the 1.3% growth in the second estimate, and market expectations of 1.4%.
    • U.S. natural-gas supplies increased 76 billion cubic feet during the week ended June 23.

    Now Read This: Top 2 Utilities Stocks That That Could Sink Your Portfolio This Quarter

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 107,303,870 cases with around 1,168,100 deaths. India confirmed a total of at least 44,994,140 cases and 531,900 deaths, while France reported over 40,136,340 COVID-19 cases with 167,640 deaths. In total, there were at least 690,913,300 cases of COVID-19 worldwide with more than 6,895,340 deaths.

    Get the next $AYI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AYI
    $BTAI
    $GNLN
    $IMNM

    CompanyDatePrice TargetRatingAnalyst
    Immunome Inc.
    $IMNM
    12/1/2025$36.00Buy
    Truist
    Acuity Inc.
    $AYI
    10/2/2025$330.00 → $390.00Buy
    TD Cowen
    Immunome Inc.
    $IMNM
    9/22/2025$26.00Buy
    Goldman
    Immunome Inc.
    $IMNM
    9/5/2025$26.00Buy
    Craig Hallum
    Acuity Inc.
    $AYI
    9/2/2025$380.00Equal Weight → Overweight
    Wells Fargo
    Immunome Inc.
    $IMNM
    4/2/2025$23.00Buy
    Lake Street
    Eco Wave Power Global AB
    $WAVE
    3/11/2025$15.00Buy
    Maxim Group
    Eco Wave Power Global AB
    $WAVE
    2/3/2025$14.00Buy
    Alliance Global Partners
    More analyst ratings

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Immunome with a new price target

    Truist initiated coverage of Immunome with a rating of Buy and set a new price target of $36.00

    12/1/25 8:29:07 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen reiterated coverage on Acuity with a new price target

    TD Cowen reiterated coverage of Acuity with a rating of Buy and set a new price target of $390.00 from $330.00 previously

    10/2/25 7:48:53 AM ET
    $AYI
    Building Products
    Consumer Discretionary

    Goldman initiated coverage on Immunome with a new price target

    Goldman initiated coverage of Immunome with a rating of Buy and set a new price target of $26.00

    9/22/25 8:31:23 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AYI
    $BTAI
    $GNLN
    $IMNM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by BioXcel Therapeutics Inc.

    SCHEDULE 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)

    2/9/26 4:13:17 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    2/6/26 5:00:36 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Greenlane Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - Greenlane Holdings, Inc. (0001743745) (Filer)

    1/27/26 5:15:34 PM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Ip Jonathan Hue-Fay

    3 - Greenlane Holdings, Inc. (0001743745) (Issuer)

    2/4/26 4:55:45 PM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    SVP & Chief Financial Officer Holcom Karen J exercised 897 shares at a strike of $239.76 and sold $1,538,110 worth of shares (4,974 units at $309.23), decreasing direct ownership by 16% to 21,523 units (SEC Form 4)

    4 - ACUITY INC. (DE) (0001144215) (Issuer)

    1/30/26 4:02:35 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    SEC Form 4 filed by Director Sachleben Mark

    4 - ACUITY INC. (DE) (0001144215) (Issuer)

    1/23/26 4:14:28 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Siegall Clay B bought $100,018 worth of shares (4,729 units at $21.15), increasing direct ownership by 0.72% to 665,254 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/30/25 6:47:24 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Siegall Clay B bought $149,053 worth of shares (7,278 units at $20.48) and gifted 200,000 shares, decreasing direct ownership by 23% to 660,525 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/22/25 7:38:54 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technical Officer Tsai Philip bought $204,900 worth of shares (10,000 units at $20.49), increasing direct ownership by 30% to 43,300 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/22/25 7:32:54 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 2, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 30,000 shares of common stock to one new employee under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $

    2/5/26 4:00:00 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

    VANCOUVER, British Columbia, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The market is waking up to a $71 billion reality[1]. We are seeing a decisive move away from broad chemotherapy and toward precision biologics like mRNA and oncolytic viruses. The FDA is actively accelerating this cycle, having granted multiple breakthrough designations in January 2026 alone for platforms that demonstrate genuine survival durability[2]. This structural realignment positions Oncolytics Biotech Inc. (NASDAQ:ONCY), Moderna (NASDAQ:MRNA), Immunome (NASDAQ:IMNM), Autolus Therapeutics (NASDAQ:AUTL), and Prelude Therapeutics (NASDAQ:PRLD) within the emerging biological innovation c

    2/5/26 9:26:03 AM ET
    $AUTL
    $IMNM
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    $AYI
    $BTAI
    $GNLN
    $IMNM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Financials

    Live finance-specific insights

    View All

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    Acuity Announces Increase in Quarterly Dividend

    Atlanta, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE:AYI) Board of Directors (the "Board") increases the quarterly dividend by 17% percent to 20 cents per share from 17 cents per share. The dividend is payable on February 13, 2026, to shareholders of record on February 2, 2026. About Acuity  Acuity Inc. (NYSE:AYI) is a market-leading industrial technology company. We use technology to solve problems in spaces, light and more things to come. Through our two business segments, Acuity Brands Lighting (ABL) and Acuity Intelligent Spaces (AIS), we design, manufacture, and bring to market products and services that make a valuable difference in people's lives. We achieve growth throug

    1/22/26 4:15:00 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    Acuity Reports Fiscal 2026 First-Quarter Results

    Delivered Net Sales of $1.1B, an Increase of 20% Compared to the Prior YearDelivered Operating Profit of $160M, Up 20% Compared to the Prior Year; Grew Adjusted Operating Profit to $196M, Up 24% Compared to the Prior YearDelivered Diluted EPS of $3.82, Up 14% Compared to the Prior Year; Grew Adjusted Diluted EPS to $4.69, Up 18% Compared to the Prior Year ATLANTA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE:AYI), ("Acuity"), a market-leading industrial technology company, delivered net sales of $1.1 billion in the first quarter of fiscal 2026 ended November 30, 2025, an increase of $192.1 million, or 20.2 percent, compared to the prior year. "We delivered strong performance in ou

    1/8/26 6:00:00 AM ET
    $AYI
    Building Products
    Consumer Discretionary

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mobiquity Technologies Inc.

    SC 13G/A - Mobiquity Technologies, Inc. (0001084267) (Subject)

    11/20/24 7:44:24 PM ET
    $MOBQ
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Immunome Inc.

    SC 13G/A - Immunome Inc. (0001472012) (Subject)

    11/14/24 9:00:58 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mobiquity Technologies Inc.

    SC 13G/A - Mobiquity Technologies, Inc. (0001084267) (Subject)

    11/14/24 7:18:49 PM ET
    $MOBQ
    Advertising
    Consumer Discretionary

    $AYI
    $BTAI
    $GNLN
    $IMNM
    Leadership Updates

    Live Leadership Updates

    View All

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eco Wave Power Boosts Board Strength with Election of Renowned Risk & Sustainability Expert Hilary Ackermann, Strengthening U.S. Strategy Ahead of Port of LA Project Official Opening

    Stockholm, Sweden--(Newsfile Corp. - July 17, 2025) - Eco Wave Power Global AB (publ) (NASDAQ:WAVE) ("Eco Wave Power" or the "Company"), a leading onshore wave energy technology company, is pleased to announce the election of Hilary E. Ackermann to its Board of Directors, following approval at the Company's Annual General Meeting (AGM).Ms. Ackermann, who previously served on Eco Wave Power's Advisory Board, is a recognized leader in energy sustainability, corporate governance, and risk management. Her transition to the formal Board of Directors reflects the Company's commitment to strengthening its global leadership team as it accelerates commercialization—particularly in the United States.

    7/17/25 9:00:00 AM ET
    $WAVE
    Electric Utilities: Central
    Utilities